These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 37453238)

  • 41. A practical guide to secondary pharmacology in drug discovery.
    Jenkinson S; Schmidt F; Rosenbrier Ribeiro L; Delaunois A; Valentin JP
    J Pharmacol Toxicol Methods; 2020 Sep; 105():106869. PubMed ID: 32302774
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Radiolabelled mass-balance excretion and metabolism studies in laboratory animals: are they still necessary?
    Obach RS; Nedderman AN; Smith DA
    Xenobiotica; 2012 Jan; 42(1):46-56. PubMed ID: 21992031
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Practical approaches to resolving reactive metabolite liabilities in early discovery.
    Dalvie D; Kalgutkar AS; Chen W
    Drug Metab Rev; 2015 Feb; 47(1):56-70. PubMed ID: 25410913
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Complicating factors in safety testing of drug metabolites: kinetic differences between generated and preformed metabolites.
    Prueksaritanont T; Lin JH; Baillie TA
    Toxicol Appl Pharmacol; 2006 Dec; 217(2):143-52. PubMed ID: 17055014
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Applicability of bioanalysis of multiple analytes in drug discovery and development: review of select case studies including assay development considerations.
    Srinivas NR
    Biomed Chromatogr; 2006 May; 20(5):383-414. PubMed ID: 16307470
    [TBL] [Abstract][Full Text] [Related]  

  • 46. High-performance liquid chromatography-tandem mass spectrometry in the identification and determination of phase I and phase II drug metabolites.
    Holcapek M; Kolárová L; Nobilis M
    Anal Bioanal Chem; 2008 May; 391(1):59-78. PubMed ID: 18345532
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Metabolite identification and profiling in drug design: current practice and future directions.
    Zhang Z; Zhu M; Tang W
    Curr Pharm Des; 2009; 15(19):2220-35. PubMed ID: 19601824
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Drug metabolism for the perplexed medicinal chemist.
    Testa B
    Chem Biodivers; 2009 Nov; 6(11):2055-70. PubMed ID: 19937836
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The emergence of the C-H functionalization strategy in medicinal chemistry and drug discovery.
    Jana R; Begam HM; Dinda E
    Chem Commun (Camb); 2021 Oct; 57(83):10842-10866. PubMed ID: 34596175
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Metabolite Identification in the Preclinical and Clinical Phase of Drug Development.
    Wu Y; Pan L; Chen Z; Zheng Y; Diao X; Zhong D
    Curr Drug Metab; 2021; 22(11):838-857. PubMed ID: 34620061
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Introduction to early in vitro identification of metabolites of new chemical entities in drug discovery and development.
    Baranczewski P; Stańczak A; Kautiainen A; Sandin P; Edlund PO
    Pharmacol Rep; 2006; 58(3):341-52. PubMed ID: 16845208
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Differentiation of Deprotonated Acyl-,
    Niyonsaba E; Easton MW; Feng E; Yu Z; Zhang Z; Sheng H; Kong J; Easterling LF; Milton J; Chobanian HR; Deprez NR; Cancilla MT; Kilaz G; Kenttämaa HI
    Anal Chem; 2019 Sep; 91(17):11388-11396. PubMed ID: 31381321
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Hepatotoxicity and hepatic metabolism of available drugs: current problems and possible solutions in preclinical stages.
    Giri S; Nieber K; Bader A
    Expert Opin Drug Metab Toxicol; 2010 Aug; 6(8):895-917. PubMed ID: 20367107
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Best practices for metabolite quantification in drug development: updated recommendation from the European Bioanalysis Forum.
    Timmerman P; Blech S; White S; Green M; Delatour C; McDougall S; Mannens G; Smeraglia J; Williams S; Young G
    Bioanalysis; 2016 Jun; 8(12):1297-305. PubMed ID: 27217058
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Metabolic activation in drug-induced liver injury.
    Leung L; Kalgutkar AS; Obach RS
    Drug Metab Rev; 2012 Feb; 44(1):18-33. PubMed ID: 21939431
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Strategies for dealing with reactive intermediates in drug discovery and development.
    Nassar AE; Lopez-Anaya A
    Curr Opin Drug Discov Devel; 2004 Jan; 7(1):126-36. PubMed ID: 14982156
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Microbial Bioconversion: A Regio-specific Method for Novel Drug Design and Toxicological Study of Metabolites.
    Yousuf M; Jamil W; Mammadova K
    Curr Pharm Biotechnol; 2019; 20(14):1156-1162. PubMed ID: 31258075
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Accessing Drug Metabolites via Transition-Metal Catalyzed C-H Oxidation: The Liver as Synthetic Inspiration.
    Genovino J; Sames D; Hamann LG; Touré BB
    Angew Chem Int Ed Engl; 2016 Nov; 55(46):14218-14238. PubMed ID: 27723189
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Discovering drugs through biological transformation: role of pharmacologically active metabolites in drug discovery.
    Fura A; Shu YZ; Zhu M; Hanson RL; Roongta V; Humphreys WG
    J Med Chem; 2004 Aug; 47(18):4339-51. PubMed ID: 15317447
    [No Abstract]   [Full Text] [Related]  

  • 60. From known knowns to known unknowns: predicting in vivo drug metabolites.
    Pelkonen O; Tolonen A; Korjamo T; Turpeinen M; Raunio H
    Bioanalysis; 2009 May; 1(2):393-414. PubMed ID: 21083174
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.